Clinical evaluation of teicoplanin in MRSA infections
スポンサーリンク
概要
- 論文の詳細を見る
The clinical efficacy and safety of teicoplanin (TEIC), a new glycopeptide antibiotic, were studied in 2 patients with pneumonia, 1 with chronic bronchitis, 1 with septicemia, and 2 with subcutaneous abscess caused by methicillin-resistant <I>Staphylococcus aureus</I> (MRSA). MICs (10<SUP>8</SUP> cells/ml) against 6 strains of MRSA were 0.78-3.13μg/ml, and serum trough levels of TEIC in 2 patients were about 4μg/ml. MRSA disappeared in 3, decreased in 1 and persisted in 2 patients, but the clinical efficacy was good in 1, fair in 1 and poor in 4 patients. The poorer than expected clinical efficacy, based on MIC and plasma levels, and bacteriological effects of TEIC were considered to be due to compromised conditions of the hosts such as the presence of cancer, surgical stress, age and malnutrition. There were no side effects, but slight and reversible elevation of eosinophils and serum transaminase were observed in 3 patients.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.